Evidence map›Paper›PMID 40539328›Full record

ArticleTissue barriers2026

Advanced glycation endproducts induce cytokine dysregulation and weaken lung epithelial and endothelial barrier integrity.

Abdulaziz H Alanazi, Mohamed S Selim, Yin Zhu, Duo Zhang, S Priya Narayanan, Payaningal R Somanath

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tissue barriers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abdulaziz H AlanaziClinical and Experimental Therapeutics, University of Georgia, Augusta, GA, USA.
Mohamed S SelimClinical and Experimental Therapeutics, University of Georgia, Augusta, GA, USA.
Yin ZhuClinical and Experimental Therapeutics, University of Georgia, Augusta, GA, USA.
Duo ZhangClinical and Experimental Therapeutics, University of Georgia, Augusta, GA, USA.
S Priya NarayananClinical and Experimental Therapeutics, University of Georgia, Augusta, GA, USA.
Payaningal R SomanathClinical and Experimental Therapeutics, University of Georgia, Augusta, GA, USA.ORCID 0000-0003-3017-0230

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is a systemic disease characterized by chronic hyperglycemia, persistent inflammation, and oxidative stress. While the vascular complications of diabetes are well-documented, their impact on lung barrier integrity remains underexplored. In this study, we investigated the molecular mechanisms by which advanced glycation end-products (AGE) compromise the integrity of lung endothelial and epithelial barriers. Using human lung microvascular endothelial cells and epithelial (A549) cells, we assessed the impact of AGE on the tight junction protein claudin-5, adherens junction protein VE-cadherin, and key signaling molecules including the receptor for AGE (RAGE), phosphorylated Akt, and p38 MAPK as well as a panel of pro-inflammatory cytokines. Our findings demonstrated that AGE exposure (50 μg/mL) significantly activated Akt and p38 MAPK, upregulated Claudin-5 and RAGE, and downregulated VE-cadherin, correlating with reduced transendothelial electrical resistance

Indexed as

CytokinesEndothelial CellsEpithelial CellsGlycation End Products, AdvancedLungHumansCytokinesGlycation End Products, AdvancedAdvanced glycation end productsdiabetes mellitusinflammationlung endothelial-barrier, macrophages, cytokines

Identifiers

PMID40539328
PMCPMC12959210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.